☆ 4.6 Article

sFlt-1/PlGF ratio test for pre-eclampsia: an economic assessment for the UK

ULTRASOUND IN OBSTETRICS & GYNECOLOGY (2016)

Journal

ULTRASOUND IN OBSTETRICS & GYNECOLOGY

Volume 48, Issue 6, Pages 765-771

Publisher

WILEY

DOI: 10.1002/uog.15997

Keywords

cost-effectiveness; diagnosis; economic; hospitalization; model; prediction; pre-eclampsia; sFlt-1/PlGF

Funding

Roche Diagnostics

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Objectives To assess the economic impact of introducing into clinical practice in the UK the soluble fms-like tyrosine kinase (sFlt-1) to placental growth factor (PlGF) ratio test for guiding the management of pre-eclampsia. Methods We used an economic model estimating the incremental value of information, from a UK National Health Service payer's perspective, generated by the sFlt-1/PlGF ratio test, compared with current diagnostic procedures, in guiding the management of women with suspected pre-eclampsia. The economic model estimated costs associated with the diagnosis and management of pre-eclampsia in pregnant women between 24+0 and 36+6weeks' gestation, managed in either a 'test' scenario in which the sFlt-1/PlGF test is used in addition to current diagnostic procedures, or a 'no-test' scenario in which clinical decisions are based on current diagnostic procedures alone. Test characteristics and resource use were derived from PROGNOSIS, a non-interventional study in women presenting with clinical suspicion of pre-eclampsia. The main outcome measure from the economic model was the cost per patient per episode of care, from first suspicion of pre-eclampsia to birth. Results Introduction of the sFlt-1/PlGF ratio test into clinical practice is expected to result in cost savings of 344 pound per patient compared with a no-test scenario. Savings are generated primarily through an improvement in diagnostic accuracy and subsequent reduction in unnecessary hospitalization. Conclusions Introducing the sFlt-1/PlGF ratio test into clinical practice in the UK was shown to be cost-saving by reducing unnecessary hospitalization of women at low risk of developing pre-eclampsia. In addition, the test ensures that those women at higher risk are identified and managed appropriately. (C) 2016 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Comparison of ophthalmic artery Doppler with PlGF and sFlt-1/PlGF ratio at 35-37 weeks' gestation in prediction of imminent pre-eclampsia

K. Lau, A. Wright, M. Sarno, N. A. Kametas, K. H. Nicolaides

Summary: This study compared the predictive performance of serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1)/PlGF ratio with the competing-risks model utilizing maternal risk factors, mean arterial pressure (MAP), and ophthalmic artery peak systolic velocity (PSV) ratio for predicting pre-eclampsia (PE) delivery. The results showed that ophthalmic artery Doppler combined with maternal risk factors and blood pressure could potentially replace the measurement of PlGF and sFlt-1/PlGF ratio in predicting imminent PE.

ULTRASOUND IN OBSTETRICS & GYNECOLOGY (2022)